MaxCyte (MXCT) (MXCT)
:MXCT
Want to see MXCT full AI Analyst Report?
MXCT Stock Chart & Stats
$0.81
-$0.03(-3.55%)
―
--
Day’s Range― - ―
52-Week Range$0.64 - $2.96
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$90.32M
Enterprise Value$88.48M
Total Cash (Recent Filing)$103.04M
Total Debt (Recent Filing)$17.94M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
May 13, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding106,861,430
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)0.96
Price to Sales (P/S)4.99
P/FCF Ratio-4.56
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue2.68
Enterprise Value/Gross Profit3.92
Enterprise Value/Ebitda-2.16
Forecast
1Y Price Target
$4.50Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$27.38M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Lower Cash BurnA large cash position with no debt and meaningful reduction in annual cash burn materially extends runway and reduces refinancing risk. This gives management time to execute product launches, support partner programs, and fund operations through H2 execution without immediate capital raises, a durable liquidity advantage.
High Gross Margins And Unit EconomicsConsistently very high gross margins reflect strong pricing power and low incremental cost to serve instruments and consumables. With fixed costs managed, these unit economics can support eventual operating leverage and profitability as revenue stabilizes and volume from the installed base grows.
Installed Base Growth Fueling Recurring RevenueAn expanding instrument installed base creates a durable recurring revenue stream from consumables and services. As customers scale cell therapy and gene editing workflows, higher utilization drives repeat PA sales and strengthens long-term revenue visibility tied to platform adoption rather than one‑off instrument sales.
Bears Say
Multi-year Revenue DeclineSustained top‑line decline undermines operating leverage and the ability to absorb fixed costs, pressuring margins and profitability despite strong gross margins. Without a clear and sustained recovery in core revenue, the business risks long-term erosion of scale economics and reduced ability to fund R&D or commercial expansion.
Persistent Negative Operating And Free Cash FlowChronic negative OCF and FCF indicate the business burns cash even with high gross margins, forcing reliance on the balance sheet or external financing. This limits strategic optionality, raises capital‑raising risk over time, and means management must sustain cost discipline while restoring revenue to achieve self‑funding operations.
SPL Concentration And Program AttritionDependence on a concentrated set of SPL partners and sensitivity to program exits creates revenue volatility and undermines milestone/royalty visibility. Terminations and reduced purchases from the largest customer show that partner dynamics can materially swing core and SPL revenue forecasts, making growth harder to predict.
MaxCyte News
MXCT FAQ
What was MaxCyte (MXCT)’s price range in the past 12 months?
MaxCyte (MXCT) lowest stock price was $0.64 and its highest was $2.96 in the past 12 months.
What is MaxCyte (MXCT)’s market cap?
MaxCyte (MXCT)’s market cap is $90.32M.
When is MaxCyte (MXCT)’s upcoming earnings report date?
MaxCyte (MXCT)’s upcoming earnings report date is May 13, 2026 which is in 25 days.
How were MaxCyte (MXCT)’s earnings last quarter?
MaxCyte (MXCT) released its earnings results on Mar 24, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.076 by -$0.014.
Is MaxCyte (MXCT) overvalued?
According to Wall Street analysts MaxCyte (MXCT)’s price is currently Undervalued.
Does MaxCyte (MXCT) pay dividends?
MaxCyte (MXCT) does not currently pay dividends.
What is MaxCyte (MXCT)’s EPS estimate?
MaxCyte (MXCT)’s EPS estimate is -0.08.
How many shares outstanding does MaxCyte (MXCT) have?
MaxCyte (MXCT) has 106,861,430 shares outstanding.
What happened to MaxCyte (MXCT)’s price movement after its last earnings report?
MaxCyte (MXCT) reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.076. Following the earnings report the stock price went down -6.892%.
Which hedge fund is a major shareholder of MaxCyte (MXCT)?
Currently, no hedge funds are holding shares in MXCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MaxCyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (― Downside)
$4.50 (― Downside)
Hedge Fund Trend
Decreased
By 692.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.3K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-24.06%
Trailing 12-Months
Asset Growth
-15.44%
Trailing 12-Months
Company Description
MaxCyte (MXCT)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
MXCT Earnings Call
Q4 2026
0:00 / 0:00
MXCT Stock 12 Month Forecast
Average Price Target
$4.50
Ownership Overview
1.85% Insiders
11.00%
Mutual Funds
0.29% Other Institutional Investors
78.37% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---